vs

Side-by-side financial comparison of Marwynn Holdings, Inc. (MWYN) and RELMADA THERAPEUTICS, INC. (RLMD). Click either name above to swap in a different company.

Marwynn Holdings, Inc. is the larger business by last-quarter revenue ($2.3M vs $1.3M, roughly 1.9× RELMADA THERAPEUTICS, INC.). On growth, RELMADA THERAPEUTICS, INC. posted the faster year-over-year revenue change (13.0% vs -13.3%).

Marwynn Holdings, Inc. is a Canada-based investment holding company focused on acquiring, managing, and scaling middle-market businesses primarily across North America. Its core operating segments cover industrial products, consumer goods, and technology-enabled services, targeting sustainable long-term value creation for its stakeholders.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system disorders. Its lead product candidate targets treatment-resistant depression, with ongoing clinical trials to address unmet medical needs in its primary markets of North America and Europe.

MWYN vs RLMD — Head-to-Head

Bigger by revenue
MWYN
MWYN
1.9× larger
MWYN
$2.3M
$1.3M
RLMD
Growing faster (revenue YoY)
RLMD
RLMD
+26.3% gap
RLMD
13.0%
-13.3%
MWYN

Income Statement — Q1 FY2026 vs Q4 FY2023

Metric
MWYN
MWYN
RLMD
RLMD
Revenue
$2.3M
$1.3M
Net Profit
$-2.7M
Gross Margin
42.4%
Operating Margin
-115.8%
-2130.6%
Net Margin
-116.0%
Revenue YoY
-13.3%
13.0%
Net Profit YoY
-11713.9%
EPS (diluted)
$-0.16
$-0.84

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MWYN
MWYN
RLMD
RLMD
Q3 25
$2.3M
Q1 25
$623.7K
Q4 23
$1.3M
Q3 23
$1.3M
Q2 23
$1.4M
Q1 23
$1.2M
Q4 22
$1.1M
Q3 22
$827.6K
Net Profit
MWYN
MWYN
RLMD
RLMD
Q3 25
$-2.7M
Q1 25
$23.4K
Q4 23
Q3 23
$-22.0M
Q2 23
$-25.3M
Q1 23
$-26.3M
Q4 22
$-37.9M
Q3 22
$-39.4M
Gross Margin
MWYN
MWYN
RLMD
RLMD
Q3 25
42.4%
Q1 25
39.2%
Q4 23
Q3 23
Q2 23
Q1 23
Q4 22
Q3 22
Operating Margin
MWYN
MWYN
RLMD
RLMD
Q3 25
-115.8%
Q1 25
13.5%
Q4 23
-2130.6%
Q3 23
-1717.3%
Q2 23
-1908.9%
Q1 23
-2331.3%
Q4 22
-3472.5%
Q3 22
-4680.6%
Net Margin
MWYN
MWYN
RLMD
RLMD
Q3 25
-116.0%
Q1 25
3.8%
Q4 23
Q3 23
-1665.0%
Q2 23
-1855.9%
Q1 23
-2179.6%
Q4 22
-3404.5%
Q3 22
-4762.9%
EPS (diluted)
MWYN
MWYN
RLMD
RLMD
Q3 25
$-0.16
Q1 25
$0.00
Q4 23
$-0.84
Q3 23
$-0.73
Q2 23
$-0.84
Q1 23
$-0.87
Q4 22
Q3 22
$-1.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MWYN
MWYN
RLMD
RLMD
Cash + ST InvestmentsLiquidity on hand
$96.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.3M
$85.4M
Total Assets
$11.6M
$97.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MWYN
MWYN
RLMD
RLMD
Q3 25
Q1 25
$480
Q4 23
$96.3M
Q3 23
$106.3M
Q2 23
$118.5M
Q1 23
$132.4M
Q4 22
$148.3M
Q3 22
$141.6M
Stockholders' Equity
MWYN
MWYN
RLMD
RLMD
Q3 25
$2.3M
Q1 25
$2.4M
Q4 23
$85.4M
Q3 23
$100.7M
Q2 23
$111.3M
Q1 23
$125.5M
Q4 22
$140.4M
Q3 22
$166.3M
Total Assets
MWYN
MWYN
RLMD
RLMD
Q3 25
$11.6M
Q1 25
$12.6M
Q4 23
$97.6M
Q3 23
$109.1M
Q2 23
$122.0M
Q1 23
$135.6M
Q4 22
$152.9M
Q3 22
$187.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MWYN
MWYN
RLMD
RLMD
Operating Cash FlowLast quarter
$-95.1K
$-10.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MWYN
MWYN
RLMD
RLMD
Q3 25
$-95.1K
Q1 25
Q4 23
$-10.2M
Q3 23
$-11.6M
Q2 23
$-13.3M
Q1 23
$-16.5M
Q4 22
$-35.9M
Q3 22
$-26.9M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MWYN
MWYN

Other$1.3M57%
Revenue From Recyclable Ewaste Materials Sales$1.0M43%

RLMD
RLMD

Segment breakdown not available.

Related Comparisons